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Introduction. Lipid-lowering drugs, especially statins, have shown great relevance in 
preventing and treating cardiovascular diseases. 
Objective. To determine the prescription patterns of lipid-lowering drugs and the 
variables associated with their use in a Colombian population 
Materials and methods. Cross-sectional descriptive study. From a drug-dispensing 
database of approximately 4.5 million Colombian health system affiliates, patients of 
all ages and both sexes treated with lipid-lowering agents (statins, fibrates, 
ezetimibe) were identified during January-March 2017. Demographic, 
pharmacological and co-medication variables were included. 
Results. In total, 103624 patients were identified as being treated with lipid-lowering 
agents. The average age was 67.5 years, and 49.8% were 65 years or older. 
Women comprised 58.0% of the patients. Statins were the most used (n=96910; 
93.5%), and atorvastatin (n=80812; 78.0%) and lovastatin (n=12621; 12.2%) were 
the most frequent. The mean atorvastatin dose was 30.3 mg/day, and 49.9% of its 
users received presentations of 40 mg or more. A total of 9258 (8.9%) patients 
received fibrates, and only 780 (0.8%) were taking ezetimibe. Of this population, 
94.9% were treated with lipid-lowering monotherapy, and 97.3% (n=100813) had co-
medication for their comorbidities, with the most frequent being antihypertensive 
(89.1%), antiplatelet (57.8%), antidiabetic (31.5%) and antiulcerative agents (34.2%). 
Conclusions. Atorvastatin is currently the most frequently used lipid-lowering drug 
in this group of Colombian patients, especially in monotherapy and at doses close to 
the defined daily dose. Only half received high-intensity doses. New studies are 
required to verify the efficacy of these therapies. 
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Introducción: Los fármacos hipolipemiantes, especialmente estatinas, han 
demostrado gran relevancia para la prevención y tratamiento de enfermedades 
cardiovasculares  
Objetivo: Determinar los patrones de prescripción de fármacos hipolipemiantes y 
las variables asociadas con su uso en una población de Colombia. 
Materiales y métodos: Estudio descriptivo transversal. A partir de una base de 
datos de dispensación de medicamentos de 4,5 millones de afiliados al sistema de 
salud de Colombia se identificaron pacientes de cualquier edad y sexo en manejo 
con hipolipemiantes (estatinas, fibratos, ezetimibe) entre enero-marzo 2017. Se 
incluyeron variables demográficas, farmacológicas y de comedicaciones.  
Resultados: Se identificaron 103.624 pacientes en tratamiento con hipolipemiantes. 
La edad promedio fue 67,5 años y el 49,8% tenían 65 años o más. El 58,0% fueron 
mujeres. Las estatinas fueron los más utilizados (n=96.910; 93,5%), siendo 
atorvastatina (n=80.812; 78,0%) y lovastatina (n=12.621; 12,2%) las más frecuentes. 
La dosis promedio de atorvastatina fue 30,3 mg/día y el 49,9% de sus usuarios 
recibían presentaciones de 40 mg o más. Un total de 9.258 (8,9%) pacientes 
recibían fibratos y solo 780 (0,8%) tomaban ezetimibe. El 94,9% de casos recibió 
tratamiento en monoterapia hipolipemiante y el 97,3% (n=100.813) tenía 
comedicaciones para comorbilidades, siendo las más frecuentes antihipertensivos 
(89,1%), antiagregantes plaquetarios (57,8%), antidiabéticos (31,5%) y antiulcerosos 
(34,2%).  
Conclusiones: Atorvastatina es actualmente el medicamento hipolipemiante más 
utilizado en este grupo de pacientes de Colombia, especialmente en monoterapia y 
a dosis cercanas a las definidas, aunque solo la mitad recibían dosis de alta 
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intensidad. Se requieren nuevos estudios que verifiquen la efectividad de estas 
terapias. 
Palabras clave: dislipidemias; ezetimiba; farmacoepidemiología; inhibidores de 
hidroximetilglutaril-CoA reductasas; hipolipemiantes; prescripciones de 
medicamentos. 
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Cardiovascular disease is a primary cause of morbidity and mortality worldwide, and 
its incidence continues to rise due to aging populations and unhealthy lifestyles (1). 
Colombia is not exempt to this situation. From 2005 to 2014, cardiovascular disease 
accounted for up to 30% of the country’s total deaths (2).  
One of the primary risk factors associated with cardiovascular disease is 
dyslipidemia, which mainly includes altered total cholesterol levels and low-density 
lipoprotein (LDL) (3). Among the drugs useful for managing dyslipidemias are statins, 
fibrates and ezetimibe. Despite its effects on plasma lipid levels, the use of some of 
these pharmacological groups is lower than expected, even in high 
cardiocerebrovascular-risk populations (4,5). 
The last study on usage patterns for this drug group in Colombia was published in 
2008, where the only statin identified was lovastatin, and gemfibrozil was the second 
most used drug, reaching 27% (6). More molecules are now available in all lipid-
lowering drug groups, and reports in Colombian populations show some changes in 
their prescriptions. For example, by the year 2013, atorvastatin had already 
displaced lovastatin as the most widely used statin drug (7,8). 
In the present work, we sought to determine the prescription patterns of lipid-
lowering drugs in patients affiliated with the Health System of Colombia (SGSSS) in 
2017, considering the possible epidemiological changes in cardiovascular disease 
and the inclusion of new lipid-lowering medications in the benefit plan offered by 
health insurance entities (Benefit Plan Administrators) (9). 
Materials and methods 
Study design 
A cross-sectional study was conducted on the prescription habits of lipid-lowering 
drugs. Information was obtained from a population database of approximately 4.5 
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million people affiliated with the SGSSS in five Benefit Plan Administrators of the 
contributory scheme, which corresponds to approximately 22.5% of the active 
population affiliated with this regime in the country and 9.3% of the Colombian 
population. 
We analyzed prescribing data from patients treated with lipid-lowering drugs 
between January 1 and March 31, 2017 in all Colombian cities with reliable 
databases. We included data on individuals of all ages and sexes who had been 
prescribed lipid-lowering drugs and whose management was uninterrupted for at 
least three months to ensure that patients stably complied with the treatment, 
reflecting medication tolerance and adherence. 
Medicine consumption information on the affiliated population was systematically 
obtained by the dispensing company (Audifarma SA). Audifarma S.A is the largest 
drug dispensing company in Colombia. Information is generated at the time of 
dispensing and stored on a server with daily dispensing data (approximately 2.8 
million formulas per month). To access the data, the Business Object tool is used on 
a platform in Oracle where all the drug claims are stored; and a database was 
designed with the following variables: 
1. Sociodemographics included sex, age, and city. 
2. Lipid-lowering drugs included statins (atorvastatin, cerivastatin fluvastatin, 
lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin), fibrates (bezafibrate, 
ciprofibrate, fenofibrate, gemfibrozil) and ezetimibe (alone or combined with statins). 
The dose and quantity delivered were recorded. The defined daily dose (DDD) was 
used as a unit of measurement for the drug use per the recommendations of the 
World Health Organization. 
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3. Co-medication was accepted as a surrogate indicator of chronic disease, 
considering the following circumstances: a) antidiabetics and insulins/diabetes 
mellitus; b) antihypertensive and diuretic/arterial hypertension; c) 
anticoagulants/thromboembolic disorders; d) levothyroxine-antithyroid/thyroid 
pathology; e) nitrovasodilators/ischemic heart disease; f) anti-ulcers/acid-peptic 
disease; g) antiplatelet drugs/cardiovascular prevention.  
Bioethics 
The protocol was endorsed by the Bioethics Committee of the Universidad 
Tecnológica de Pereira and was classified in the category of "risk-free research". 
Patients’ personal data were not used, and their identities were safeguarded per the 
recommendations of the Declaration of Helsinki. 
Data analyses 
Descriptive statistics were used to analyze the data using the statistical package 
SPSS version 24.0 (IBM, USA) for Windows. Bivariate tests were also performed, 
such as Student's t-test to compare quantitative variables, and χ2 for categorical 
variables. We prepared binary logistic regression models using lipid-lowering drug 
use alone or in combination therapy (yes/no) and the need for co-medication 
(yes/no) as dependent variables. The covariates in these models included age, sex 
and the variables that were significantly associated with the dependent variables in 
the bivariate analyses. The statistical significance level was p < 0.05. 
Results 
We identified 103,624 patients affiliated with the SGSSS being treated with lipid-
lowering drugs continuously during the study period. The average age was 67.5 ± 
12.1 years (range: 18-105 years), and the sex distribution showed that 60,098 
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(58.0%) were women. People aged 65 years and older represented 49.8% 
(n=51,615) of the population (figure 1).  
Of the population, 93.5% (n=96,910) received treatment with some statin, with 
atorvastatin being the most used (n=80,812; 78.0% of the total population), followed 
by lovastatin with 12,621 patients (12.2%). The main presentations dispensed were 
atorvastatin tablets 20 mg (n=42,389; 52.4% of those with atorvastatin) and 40 mg 
(n=39,724; 49.2%), but 3,210 (4.0%) received 10 mg, and 634 received 80 mg 
(0.8%). All lovastatin was prescribed as 20 mg. Only 4 patients received pitavastatin, 
and no formulations of cerivastatin, fluvastatin and pravastatin were found.  
A total of 9,258 (8.9%) patients received fibrates, mainly gemfibrozil (n=8,242; 8.0% 
of the total subjects). Seven hundred eighty patients (0.8%) used some form of 
ezetimibe. Table 1 shows the prescription patterns of each of these drug groups.  
The relationship between the average dose administered and the DDD varied 
greatly, with values from 0.44 for lovastatin to 2.53 for rosuvastatin (table 1). A total 
of 40,358 patients with atorvastatin (38.9% of the total population and 49.9% of 
those with atorvastatin) were receiving presentations of 40 mg or more, while 5,274 
patients received rosuvastatin 20 mg or more (5.1% of all patients and 94.0% of 
rosuvastatin users). 
Monotherapy versus combination therapy 
A total of 98355 patients (94.9%) used a single lipid-lowering drug during the study 
period, while 5,190 (5.0%) used a combination of two drugs, and 79 cases received 
three medications. Figure 2 shows the distribution of the main lipid-lowering agents 
used by monotherapy or combination therapy.  
The most frequent association was atorvastatin + gemfibrozil (n=1,986 patients, 
1.9% of all patients). Multivariate analysis of the relationship between the use of 
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combination lipid-lowering therapy and other variables showed that the concomitant 
use of antidiabetics, thiazide diuretics, minoxidil and proton pump inhibitors 
increased the probability of receiving therapy with more than one lipid-lowering drug. 
In contrast, being 65 years of age or older and using apixaban reduced this 
probability (Table 2). 
Co-medication 
Most study patients (97.3%, n=100813) used some co-medication. The average 
number of co-medications per patient was 4.0 ± 2.0 (range: 0-14 different drugs). 
The drugs for other comorbidities most frequently identified were antihypertensive 
drugs (n=92,338; 89.1%), antiplatelet agents (n=59,890; 57.8%, and 97.8% 
corresponded to acetylsalicylic acid), antidiabetics (n=32,609; 31.5%, of which 
30.4% used insulins) and antiulcer drugs (n=35.397; 34.2%, where 92.2% 
corresponded to proton pump inhibitors).  
We identified 28,562 patients (27.6%) consuming antihypertensive and antidiabetic 
medications concomitantly. Of diabetic patients, 87.6% received an antihypertensive, 
while 30.9% of hypertensive patients used antidiabetics. 
In the antihypertensive group, 41510 patients (40.1% of the total patients, 45.0% of 
those with antihypertensive drugs) received a combination of two drugs in this group, 
and 17589 (17.0%) received three. The most prescribed group was angiotensin II-
receptor antagonists (especially losartan) in 65416 patients (63.1%), followed by β-
adrenergic blockers (33.3%), calcium channel blockers (32.9%), thiazide diuretics 
(23.3%) and angiotensin-converting enzyme inhibitors (17.2%). 
Other medications included those used to treat thyroid disease (n=18242, 17.6%), 
loop diuretics (n=15063, 14.5%), aldosterone inhibitors (n=5501, 5.3%), 
anticoagulants (n=3405, 3.3%), nitrovasodilators (n=1326, 1.3%) and arterial 
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vasodilators (n=73, 0.1%). Table 3 shows the sociodemographic and 
pharmacological variables of patients receiving lipid-lowering drugs by co-
medications or comorbidities. 
Multivariate analysis of the outcome of receiving some co-medication in patients 
being treated with lipid-lowering drugs indicated that being 65 years of age or older 
and using non-combined presentations of lovastatin, atorvastatin, rosuvastatin and 
fibrates were associated with a higher probability of receiving co-medication. 
Ezetimibe use was associated with a lower probability of receiving co-medication 
(Table 4). 
Comparison between cities  
Demographic variables and some prescription indicators were compared among the 
105 Colombian cities included in this study. The different characteristics and 
proportions of lipid-lowering drug use in the eight main cities are summarized in table 
5. 
Discussion 
In the present work, the utilization profile of the main lipid-lowering drugs used in an 
insured population of the Colombian health system was described, finding large 
differences from data previously reported in the country. 
The average age of those who use these medications is consistent with the profile of 
dyslipidemia and cardiovascular disease (2,10). The predominance of females 
attracts attention because men experience greater mortality and more years of life 
potentially lost due to this group of pathologies (2), although in Colombia, mixed 
dyslipidemia has been described as the most common and that it presents more 
frequently in women (10).  
13 
 
During the study period, the most used drug group was the statins, encompassing 
over 90% of the total prescriptions, while fibrates only accounted for approximately 
9%. This shows an important change regarding the 2008 data, where statins, despite 
also being the most consumed, only encompassed 71% of total prescriptions and 
fibrates comprised 27% (6). As mentioned above, for 2008, the dominant statin was 
lovastatin because it was the only one included on the SGSSS benefit plan’s drug 
list. The change in the prescription pattern to atorvastatin, until now the dominant 
drug, was likely due to its inclusion in the benefit plan (9) and because higher doses 
can be achieved, which improves the therapy’s intensity and therefore the expected 
efficacy (11-13). 
This change towards increased atorvastatin prescriptions is also supported by 
previous national study results, which found that patients treated with lovastatin were 
less likely to achieve metabolic control (although it was used at doses lower than 
those recommended, similar to the present study) (8). In addition, atorvastatin has 
been identified as the most cost-effective option for patients with dyslipidemia in the 
Colombian health context when moderate to high intensity treatments are required 
(14). When comparing these results with studies from other countries, atorvastatin 
has also been the most prescribed in Taiwan, but only at 37% (15), whereas 
research in Italy and Brazil found a predominance of simvastatin (16,17). 
In the present study, more than a third of the population was receiving statins at high 
intensity doses by international standards (atorvastatin 40-80 mg, rosuvastatin 20-40 
mg) (12). In a sample of Colombian patients receiving lipid-lowering drugs, according 
to the Framingham scale, 94% of these patients had a moderate to high 
cardiovascular risk (10), which is why it would be expected that more patients in the 
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study were receiving high doses of these drugs in addition to the indications of 
national and international management guidelines (12,13). 
Lipid-lowering drug use in combination therapy was 5%, which is similar to previous 
national reports (8) and works published in France (18) and the United States (19). 
Concomitantly using statins with fibrates is usually avoided due to the increased risk 
of adverse reactions, which has been documented in pharmacoepidemiological 
studies (19); therefore, the high monotherapy frequency seems appropriate, 
although in adequately selected patients with residual cardiovascular risk, 
combination therapy may be a therapeutic option of interest to achieve goals (20) 
with fibrates as well as ezetimibe (21), and more recently with new therapeutic 
options such as PCSK9 (3). 
The comorbidities and co-medications found in the study population are consistent 
with the profile associated with patients requiring lipid-lowering drugs. Therefore, 
antihypertensive, antiplatelet and antidiabetic agents were the dominant co-
medications, as has been described in other studies (8). It is striking that in this 
patient group, antiplatelet agents reached a usage near 60%, much higher than the 
value of 3.8% reported in 2008, indicating an improvement in preventing 
cardiovascular risk among this type of patients (6). 
 The worldwide tendency is to increase prescriptions of lipid-lowering drugs in 
patients with diabetes mellitus (22), because the recommended use of statins is 
growing in patients with this comorbidity as a routine step for prevention of 
cardiovascular events, which was also identified in this study (increasing from 20% in 
2008 to 32% in 2017) (6). The high use of anti-ulcerative drugs has been described 
previously, especially in chronic disease populations, often without a clear indication 
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(23), although in this case, it can be explained by the high prescription of antiplatelet 
agents in elderly patients. 
Another interesting aspect is the relationship found between ezetimibe use and the 
lower probability of having co-medications, especially because ezetimibe has been 
described as a useful medication to achieve goals in patients with dyslipidemia who 
also have multiple comorbidities (24). Residual confounders not considered during 
the study may explain this relationship, such as the patient’s educational levels or 
socioeconomic statuses (25), aspects of health and insurance services, preferences 
of prescribing physicians or the presence of clinical inertia to reach goals in 
dyslipidemia in patients with multiple pathologies (26). 
 Differences between prescription profiles in different cities (for example, variations in 
the prevalence of rosuvastatin use) are frequent in pharmacoepidemiological studies 
(6) and have been associated with local differences in health services, medical 
training or inhabitants’ characteristics (27). 
This research has some limitations. Because the results came from dispensing 
databases, and clinical records were not consulted, variables such as patients' 
cardiovascular risk, lipid profiles, efficacy or the presence of adverse reactions were 
not analyzed. Likewise, the patterns found are applicable only to populations with 
insurance characteristics similar to the study subjects. New research is required to 
determine detailed aspects of using these drugs, for example, by the indication of 
treatment in the field of primary and secondary cardiovascular disease prevention.  
The prescription patterns identified in this study highlight that the main lipid-lowering 
drug dispensed in Colombia is atorvastatin, especially in monotherapy and at doses 
close to DDD. Regarding previous analyses, the prescriptions differed considerably, 
likely due to modifications in the drugs included in the benefit plans and the evidence 
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presented in different clinical guides, highlighting the increase in useful co-
medications for cardiovascular prevention such as antiplatelet drugs. These data 
may be useful for professionals and health administrators to define behaviors related 
to managing cardiovascular risk in the Colombian population, since there seems to 
be an opportunity for improvement related to a probable underuse of statins at high 
doses in patients who require them. The adequate management of dyslipidemias 
can have a long-term impact on public health by reducing cardiovascular risk, 
morbidity and mortality secondary to ischemic events, heart failure and, in addition, 
the costs derived from their attention. 
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Figure 1. Distribution of 103,624 patients treated with lipid-lowering drugs, by age 
and sex, Colombia, 2017.  
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Figure 2. Frequency of prescription of the main lipid-lowering drugs used, alone or in 
combination therapy, Colombia, 2017.  
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Table 1. Prescription patterns of lipid-lowering drugs used in 103,624 patients in 
Colombia, 2017.  
Medication 
Prescription/users   Dose (mg/day) 
DDD 
Female : Male 
ratio 
Mean 
age # Patients %   Mean Median 
Statins* 96.910 93.5         1.4 : 1 67.8 
Atorvastatin 80.812 78.0   30.3 26.7 1.52 1.4 : 1 67.8 
Lovastatin 12.621 12.2   19.9 20.0 0.44 1.7 : 1 68.2 
Rosuvastatin 5.609 5.4   25.3 18.7 2.53 1.3 : 1 65.6 
Simvastatin 343 0.3   29.3 24.9 0.98 1.1 : 1 67.2 
                  
Fibrates 9.258 8.9         1.0 : 1 63.2 
Gemfibrozil 8.242 8.0   628.6 600.0 0.52 1.1 : 1 63.5 
Fenofibrate 591 0.6   186.4 200.0 0.93 0.8 : 1 61.3 
Ciprofibrate 471 0.5   97.5 100.0 0.97 0.7 : 1 60.6 
                  
Ezetimibe 780 0.8   9.0 9.3 0.90 0.9 : 1 65.3 
Ezetimibe 10mg 262 0.3   8.1 6.7 0.67 1.0 : 1 65.0 
Combined presentations 524 0.5   9.3 9.3 0.93 0.9 : 1 65.6 
DDD: average ratio between the prescribed daily dose and the defined daily dose. * Only 4 patients were 
receiving pitavastatin during the study time 
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Table 2. Variables associated with combined lipid-lowering therapy in binary logistic 
regression models, Colombia 2017.  
 
Variables Sig. OR 
95% CI 
Lower Upper 
Age ≥65 years <0.01 0.75 0.70 0.80 
Male sex 0.10 1.05 0.99 1.12 
Use of:         
Antidiabetics <0.01 1.12 1.05 1.20 
Thiazide diuretics <0.01 1.18 1.10 1.27 
Alpha-blockers 0.09 0.87 0.74 1.02 
Minoxidil  0.04 2.41 1.03 5.68 
Apixaban 0.04 0.48 0.24 0.96 
Proton pump inhibitors <0.01 1.16 1.09 1.24 
Living in Cali city <0.01 1.428 1.30 1.57 
Constant 0.00 0.05     
Sig: Significance; OR: Odds ratio; 95 % CI: Confidence interval of 95 %. 
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Table 3. Comparison of lipid-lowering prescriptions according to comorbidity, 
Colombia, 2017.  
Variable 
Anti 
hypertensive 
Antplatelet 
drugs 
Antidiabetics 
Antiulcer 
drugs 
Thyroid 
hormone 
Loop 
diuretic 
Aldosterone 
inhibitors 
Anticoagul
ants 
n=92338 n=59890 n=32609 n=35397 n=18242 n=15.063 n=5501 n=3405 
Mean age (years) 68.1 68.8 67.3 69.5 69.5 73.4 70.1 71.4 
Women (%) 53480 (57.9) 32478 (54.2) 18290 (56.1) 22753 (64.3) 13.197 (72.3) 8619 (57.2) 2692 (48.9) 1650 (48.5) 
Polytherapy (%) 4659 (5.0) 3068 (5.1) 1793 (5.5) 1924 (5.4) 969 (5.3) 742 (4.9) 272 (4.9) 153 (4.5) 
                  
Prescription- n (%)                 
Statins 87167 (94.4) 56878 (95.0) 30477 (93.5) 33515 (94.7) 17.305 (94.9) 14432 (95.8) 5391 (98.0) 3344 (98.2) 
Atorvastatin 72875 (78.9) 48175 (80.4) 25739 (78.9) 28547 (80.6) 14.475 (79.3) 12464 (82.7) 4757 (86.5) 2915 (85.6) 
Lovastatin 11406 (12.4) 6841 (11.4) 3484 (10.7) 3632 (10.3) 2.316 (12.7) 1548 (10.3) 374 (6.8) 262 (7.7) 
Rosuvastatin 4904 (5.3) 3222 (5.4) 1939 (5.9) 2159 (6.1) 910 (5.0) 741 (4.9) 396 (7.2) 252 (7.4) 
Simvastatin 234 (0.3) 152 (0.3) 99 (0.3) 97 (0.3) 78 (0.4) 34 (0.2) 25 (0.5) 15 (0.4) 
                  
Fibrates 7437 (8.1) 4475 (7.5) 3081 (9.4) 2830 (8.0) 1.407 (7.7) 1006 (6.7) 205 (3.7) 102 (3.0) 
Gemfibrozil 6891 (7.5) 4136 (6.9) 2729 (8.4) 2571 (7.3) 1.266 (6.9) 924 (6.1) 168 (3.1) 76 (2.2) 
Fenofibrate 327 (0.4) 196 (0.3) 222 (0.7) 153 (0.4) 73 (0.4) 48 (0.3) 20 (0.4) 18 (0.5) 
Ciprofibrate 254 (0.3) 164 (0.3) 154 (0.5) 122 (0.3) 75 (0.4) 42 (0.3) 18 (0.3) 9 (0.3) 
                  
Ezetimibe 494 (0.5) 339 (0.6) 211 (0.6) 196 (0.6) 132 (0.7) 62 (0.4) 51 (0.9) 34 (1.0) 
Ezetimibe 10mg 156 (0.2) 113 (0.2) 58 (0.2) 62 (0.2) 26 (0.1) 18 (0.1) 19 (0.3) 12 (0.4) 
Combined 
presentations 339 (0.4) 
227 (0.4) 154 (0.5) 135 (0.4) 106 (0.6) 45 (0.3) 32 (0.6) 22 (0.6) 
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Table 4 Variables associated with lipid-lowering therapy with co-medication in binary 
logistic regression models, Colombia, 2017.  
Variables Sig. OR 
95% CI 
Lower Upper 
Age ≥65 years <0.01 3.54 3.22 3.88 
Male sex 0.22 1.05 0.97 1.15 
Use of*:         
Lovastatin <0.01 6.70 5.22 8.60 
Atorvastatin <0.01 8.53 6.86 10.60 
Simvastatin 0.52 0.76 0.33 1.77 
Rosuvastatin <0.01 3.32 2.60 4.24 
Ezetimibe <0.01 0.24 0.17 0.33 
Fibrates <0.01 1.64 1.32 2.04 
Constant 0.00 3.32     
Sig: Significance; OR: Odds ratio; 95 % CI: Confidence interval of 95 %. 
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Table 5. Comparison of demographic variables and indicators of lipid-lowering 
prescriptions in eight Colombian cities, 2017.  
  Bogotá Pereira Cali Cartagena Barranquilla Manizales Ibagué Palmira Colombia 
  n=32670 n=9378 n=8969 n=6022 n=5520 n=4155 n=3488 n=3174 n=103624 
Mean age (years) 64.8 68.8 71.9 66.1 67.8 66.6 67.0 70.8 67.5 
Women (%) 18921 (57.9) 5504 (58.7) 5389 (60.1) 3370 (56.0) 3126 (56.6) 2512 (60.5) 2081 (59.7) 1933 (60.9) 60098 (58.0) 
Polytherapy (%) 1570 (4.8) 348 (3.7) 593 (6.6) 260 (4.3) 285 (5.2) 165 (4.0) 163 (4.7) 202 (6.4) 5269 (5.1) 
Comedication (%) 31403 (96.1) 9176 (97.8) 8683 (96.8) 5934 (98.5) 5449 (98.7) 4023 (96.8) 3428 (98.3) 3119 (98.3) 100813 (97.3) 
                    
Prescription - n (%)                   
Statins 30783 (94.2) 9000 (96.0) 8104 (90.4) 5795 (96.2) 5313 (96.3) 3973 (95.6) 3214 (92.1) 2795 (88.1) 96910 (93.5) 
Atorvastatin 25131 (76.9) 7290 (77.7) 7136 (79.6) 4677 (77.7) 4596 (83.3) 2811 (67.7) 2618 (75.1) 2274 (71.6) 80812 (78.0) 
Lovastatin 4774 (14.6) 1375 (14.7) 1019 (11.4) 289 (4.8) 259 (4.7) 1079 (26.0) 426 (12.2) 497 (15.7) 12621 (12.2) 
Rosuvastatin 1571 (4.8) 506 (5.4) 105 (1.2) 982 (16.3) 604 (10.9) 169 (4.1) 241 (6.9) 92 (2.9) 5609 (5.4) 
Simvastatin 171 (0.5) 25 (0.3) 37 (0.4) 9 (0.1) 10 (0.2) 2 (0.0) 3 (0.1) 13 (0.4) 343 (0.3) 
                    
Fibrates 2549 (7.8) 507 (5.4) 1199 (13.4) 318 (5.3) 332 (6.0) 249 (6.0) 359 (10.3) 480 (15.1) 9258 (8.9) 
Gemfibrozil 2269 (6.9) 433 (4.6) 1083 (12.1) 295 (4.9) 300 (5.4) 200 (4.8) 341 (9.8) 380 (12.0) 8242 (8.0) 
Fenofibrate 148 (0.5) 55 (0.6) 67 (0.7) 17 (0.3) 15 (0.3) 28 (0.7) 4 (0.1) 77 (2.4) 591 (0.6) 
Ciprofibrate 138 (0.4) 22 (0.2) 50 (0.6) 7 (0.1) 19 (0.3) 22 (0.5) 17 (0.5) 31 (1.0) 471 (0.5) 
                    
Ezetimibe 314 (1.0) 49 (0.5) 124 (1.4) 22 (0.4) 14 (0.3) 18 (0.4) 3 (0.1) 44 (1.4) 780 (0.8) 
Ezetimibe 10mg 57 (0.2) 23 (0.2) 72 (0.8) 8 (0.1) 2 (0.0) 9 (0.2) 1 (0.0) 13 (0.4) 262 (0.3) 
Combined 
presentations 257 (0.8) 
26 (0.3) 56 (0.6) 14 (0.2) 12 (0.2) 9 (0.2) 2 (0.1) 31 (1.0) 524 (0.5) 
 
 
 
 
